Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Item

http://www.wikidata.org/entity/Q39484956

Q39484956

about

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205 HIV-1 neutralizing antibodies: understanding nature's pathways Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 ΔCFI shows variability in the V1 and V2 regions.Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.

P2860

Q24561905-36745D92-4204-402A-B970-7A033CC3415D Q24681004-428E80F7-197C-4634-B855-DB7A3B405B90 Q27000480-D834AA93-C52D-4867-BD1C-88CFB9C84E21 Q27489000-F0C3C4AA-BBB4-4CA4-A2B5-58A7432E0EC6 Q28299280-43882044-F0DE-47E9-B4F6-B61E5E4A9730 Q28394899-B666AEB3-1008-4403-A8DC-7CB7A03A2C44 Q28533970-166B14F0-17A6-4836-AB08-C94379B6ECC3 Q28534454-97D876D0-3C73-4DC4-B771-421B6E57F940 Q28730561-5181A681-B4E5-46B4-ABC3-9FC6E118713E Q28732438-62FFC71F-6508-4E1D-B8CF-0494AAEAF914 Q29619015-73C20AFA-26F2-4D8C-A6D6-4C539B60D355 Q30379200-5591C9DF-97A4-48B1-BD49-BB8969FD772E Q30381447-67EDBC12-43B1-46CE-BD33-5D56CC491FEC Q30499590-F161BBC1-1CB4-40DA-9A41-B37DDA9CFEF3 Q33373664-33FE2050-51F7-44D1-B132-184269DA4A12 Q33571825-35538455-6C15-4B0D-8797-9C5D34D840ED Q33611645-07976C6D-4A81-4CB2-862B-8420FD49AC2C Q33614605-AF5C7FEE-C18B-4224-B25E-0074D179E83D Q33648910-D26D7836-F84F-4EF4-AD1A-75B82A632859 Q33717477-7A2B116D-DCBA-411B-A508-970D8843F58E Q33737723-FC73D038-B41E-434C-81CA-3FAC3608C1D8 Q33877513-A7197B11-8E8D-4F8B-864B-D57BCA516777 Q33883936-8550127D-B40C-4011-8624-DC016FF1AD91 Q33911986-5DA0C04F-ECB0-4172-B576-07514CEAECC4 Q34117097-5C01B6A8-10D4-4109-A03A-0F1DF7D44CFB Q34142795-CEB9C45F-F9A1-4339-9391-85AF28464B27 Q34299053-9EBCCDF6-AF34-4AA1-B984-9EBEF265AC39 Q34302085-95C14497-00AD-4326-A1BD-1BB2AF4D40C1 Q34477471-F9F2B65A-48FE-47AD-BF4E-7C594F258A0A Q34594513-044478D5-AEB8-4FC8-A52C-3B80ED6D2E6C Q34743297-0A978DEF-4341-4659-B100-FD8F9C19C949 Q34784833-5512BA34-6E54-43B2-B90A-C9CAAF79EB57 Q34807480-CBD32001-54E2-4F30-BFB3-878922E03526 Q34982715-819407DC-2030-4D49-BFA6-5AC03180FF71 Q35024202-0BDA01E6-7881-43F5-B25E-44B5042691A8 Q35065249-74480E97-D109-4AC5-8269-53316F3C6554 Q35077716-7A867242-E322-4248-96E4-DB6D3DAA255E Q35110976-0AC36547-0FD7-4CE8-9084-A11CE09A36B2 Q35666057-2E7726D3-147D-45CA-8961-46A6AA2D8BE1 Q35667479-69AA7367-C62B-48FC-8E4B-AB667D4C66C5

P2860

Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Item

http://www.wikidata.org/entity/Q39484956

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Purification, characterization ...... ficiency virus type 1 isolate.

@en

Purification, characterization ...... ficiency virus type 1 isolate.

@nl

type

Item

label

Purification, characterization ...... ficiency virus type 1 isolate.

@en

Purification, characterization ...... ficiency virus type 1 isolate.

@nl

prefLabel

Purification, characterization ...... ficiency virus type 1 isolate.

@en

Purification, characterization ...... ficiency virus type 1 isolate.

@nl

P1476

Purification, characterization ...... ficiency virus type 1 isolate.

@en

P2093

Claudio Vita

http://www.w3.org/2001/XMLSchema#string

David C Montefiori

http://www.w3.org/2001/XMLSchema#string

Elaine Kan

http://www.w3.org/2001/XMLSchema#string

Indresh K Srivastava

http://www.w3.org/2001/XMLSchema#string

Jeffrey B Ulmer

http://www.w3.org/2001/XMLSchema#string

John Donnelly

http://www.w3.org/2001/XMLSchema#string

Kenneth H Roux

http://www.w3.org/2001/XMLSchema#string

Leonidas Stamatatos

http://www.w3.org/2001/XMLSchema#string

Loic Martin

http://www.w3.org/2001/XMLSchema#string

Lucia Vojtech

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding

Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly

Atomic structure of the ectodomain from HIV-1 gp41

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein

The antigenic structure of the HIV gp120 envelope glycoprotein

Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells

P304

11244-11259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.77.20.11244-11259.2003

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9077123

http://www.w3.org/2001/XMLSchema#string

P698

14512572

http://www.w3.org/2001/XMLSchema#string

P932

224963

http://www.w3.org/2001/XMLSchema#string

Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

about

P2860

P2860

Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932